May 13, 2022 — Bristol Myers Squibb’s mavacamten will stand rather unchallenged in the hypertrophic cardiomyopathy (HCM) ...
Pharmaceuticals
This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.
May 13, 2022
May 5, 2022 — High-level results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a ...
May 05, 2022
April 29, 2022 — Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Camzyos ...
April 29, 2022
April 12, 2022 – A majority of patients with obstructive hypertrophic cardiomyopathy (HCM)—a condition that results in ...
April 12, 2022
April 8, 2022 – Patients taking renin-angiotensin-aldosterone system inhibitor (RAASi) medications for heart failure had ...
April 08, 2022
April 7, 2022 – Patients treated with the blood thinner edoxaban for six months after a heart valve replacement ...
April 07, 2022
April 7, 2022 – While there are effective therapies to reduce the risk of heart disease by lowering low-density ...
April 06, 2022
April 4, 2022 – Esperion presented two new analyses from its clinical development program of bempedoic acid (NEXLETOL) ...
April 04, 2022
March 31, 2022 – Windtree Therapeutics, a biotechnology company focused on advancing multiple late-stage interventions ...
March 31, 2022
March 22, 2022 – Fresenius Kabi, a global health care company that specializes in medicines and technologies for ...
March 22, 2022
March 4, 2022 – NewAmsterdam Pharma (NAP), a clinical-stage company focused on the research and development of ...
March 04, 2022
February 24, 2022 — The U.S. Food and Drug Administration approved Jardiance (empagliflozin) to reduce the risk of ...
February 24, 2022
January 5, 2022 — The Feinstein Institutes for Medical Research, the science arm of Northwell Health, recently received ...
January 05, 2022
January 4, 2022 — The Omicron variant, as of Dec. 25, made up 58.6% of new COVID-19 infections in the U.S., according to ...
January 04, 2022
January 4, 2022 —  The U.S. Food and Drug Administration (FDA) has cleared Novartis' inclisiran (Leqvio), the first ...
January 04, 2022© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now